VentiRx Gets $25M In Series A Extension

San Diego-based biopharmaceuticals firm VentiRx Pharmaceuticals said today that the firm has raised $25M in a Series A extension round. The firm, which is developing treatments for cancer, respiratory, and inflammatory disease, said the round was led by MedImmune Ventures, and also included prior investors ARCH Venture Partners, Domain Associates, and Frazier Healthcare Ventures. The firm said the new funding, including its initial $26.6M, Series A funding in March of 2007, brings its total raised to $51.6M. Maggie Flanagan LeFlore, Ph.D., of MedImmune Ventures, joins its board as part of the funding. More information »